- Home
- WDH vs FHTX Comparison
WDH vs FHTX Comparison
Compare WDH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDH | FHTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 419.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WDH | FHTX |
|---|---|---|
| Price | $0.98 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 210.8K | ★ 326.8K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | $8.71 | $20.13 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $0.96 | $3.27 |
| 52 Week High | $2.18 | $7.61 |
Technical Indicators
Market Signals| Indicator | WDH | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 45.66 |
| Support Level | $0.96 | $4.43 |
| Resistance Level | $1.02 | $5.93 |
| Average True Range (ATR) | 0.01 | 0.46 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 31.96 | 16.90 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.